AzTrials
AzTrials

Infertility, MaleNCT04864314

Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility

A study testing Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity in people with Infertility, Male, run by Fitoplancton Marino, S.L. at 2 sites in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

TetraSOD® is a unique marine phytoplankton (Tetraselmis chuii) SOD-rich ingredient that is grown under patent-protected technology exclusively designed by the company Fitoplancton Marino, S.L. (Spain). Read more about this study

Who is it for?
Ages 18 to 45 years, men only
Conditions the study is for
Infertility, Male
What is being tested?
Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
2 sitesSpain
Study dates
12 May 2021to 31 Oct 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Men only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age: 18 to 45
  • Male patients with idiopathic infertility classified with asthenozoospermia, oligozoospermia or oligoasthenozoospermia after seminal assessment.
  • Not achieving pregnancy after at least one year of intercourse with the same partner without protective measures

Who cannot join

  • Azoospermia (absence of spermatozoa) or severe oligozoospermia (< 5 million spermatozoa/ml of ejaculate)
  • Testicular torsion or prostatitis
  • Urinary retention and infections
  • Drug consumption
  • Hormone treatments
  • Recent surgical interventions
Show all 16Show fewer
  • Diabetes
  • Kidney or liver disease
  • Leukocytosis
  • Antioxidant supplement consumption in the last 3 months
  • BMI >30 Kg/m^2
  • Endocrinopathies, hypo and hyperthyroidism
  • Chromosomal anomalies (XX, XYY, XXY)
  • Treatments with anticoagulants
  • Radiotherapy/Chemotherapy
  • Participation in another clinical study prior to inclusion in this study that could affect the objectives of the current study

Trial locations and contacts

2 sites in 1 country.

Spain2 sites
  • Hospital Clinic

    Barcelona, 08036

  • Hospital Clinic

    Barcelona

Other trials in Spain

About this study

Official title: A Double-blind Randomized Placebo-controlled Clinical Study to Verify the Efficacy of TetraSOD® in the Improvement of Semen Quality in Patients With Idiopathic Infertility

TetraSOD® is a unique marine phytoplankton (Tetraselmis chuii) SOD-rich ingredient that is grown under patent-protected technology exclusively designed by the company Fitoplancton Marino, S.L. (Spain). In a previous pilot trial, the ability of TetraSOD® to improve semen characteristics in idiopathic infertile men after three months of treatment was assessed, revealing significant improvements in almost all of the analyzed parameters. In the present clinical trial, such positive effects will be tested again in a higher number of patients, and additional parameters will be included in order to gain insights into the sperm physiological changes that underpin the improvement in semen quality

Read the detailed description

IInfertility is an increasing global public health problem present in about 15-20% of the population of reproductive age, affecting as many as 186 million people worldwide. A male factor is present in approximately 50% of the infertile couples, a large number of them of unknown or idiopathic origin.

Spermatogenesis is a complex biological process that requires a highly regulated genetic and hormonal program in a singular environment created by the interaction with different cell types to orchestrate a successful differentiation process. This process occurs periodically every 72 days during a man's fertile life. It has been demonstrated that semen quality is deteriorating over the time, perhaps as a result of exposition to several environmental factors related with lifestyle: drug use (such us tobacco, alcohol, marijuana, cocaine, opioids and anabolic agents), diet and overweight, disorders of the sleep-wake cycle and working conditions (continuous exposition to heat sources or toxic substances) that could impact both directly and indirectly on the complex process of spermatogenesis.

Currently, the impact of oxidative stress, a cellular state product of an imbalance between the generation of highly unstable molecules known as reactive oxygen species (ROS) and the antioxidant cellular capacity in male fertility is being deeply investigated. High levels of oxidative stress in semen have been associated with both lower sperm concentration, sperm motility and acrosome integrity and higher sperm DNA damage and mitochondrial activity. Recent clinical trials have demonstrated the high prevalence of sperm DNA damage by up to 80% of men diagnosed with idiopathic male infertility. This DNA damage produced during spermatogenesis or sperm maturation process could be the result of an increase of reactive oxygen species (ROS) in male reproductive tract, which are related to different known factors (chronic systemic disease, use of some drugs, radiation or pesticides, febrile processes, old age and environmental factors related to lifestyle: smoking, obesity, alcohol) and other unknown so far.

Antioxidant supplementation has gained relevance within routine practices in patients with reproductive problems. Different studies have shown the beneficial effect of antioxidant consumption against oxidative damage caused by environmental and pathological components, improving sperm characteristics associated with the seminal analysis. There are scientific evidences about the improvement of male fertility and higher rates of live newborn after antioxidant treatment in subfertile men.

TetraSOD® is a unique commercial product comprised of 100% lyophilized biomass of the marine microalgae Tetraselmis chuii strain CCFM03 (Culture Collection of Fitoplancton Marino 03), which is currently marketed for food and nutraceutical applications around the world by the company Fitoplancton Marino, S.L. This microalgae product is characterized by a high content in the antioxidant enzyme superoxide dismutase (SOD), as it is produced using own (patent pending) technology developed by the company. Results of in vitro studies with human cell lines suggest that TetraSOD® stimulates the cellular protective mechanisms against oxidative stress. Moreover, results previously obtained in a pilot study with the highest dose of TetraSOD® (250 mg/day) were promising, since a high statistically significant response was observed in three of the four studied parameters after three months of treatment.

Taking into account these results, a new extended double-blind randomized and placebo-controlled clinical study will be performed to confirm the positive effects of dietary supplementation with 250 mg of TetraSOD® during 3 months (corresponding to the time of a complete spermatogenic cycle) in sperm quality.

The main objective of our study is to demonstrate the usefulness and safety of TetraSOD® treatment in the improvement of sperm quality including sperm DNA fragmentation. As we previously mentioned, oxidative stress is one of the main causes of sperm DNA damage. Nowadays, a diagnostic test for the study of the sperm DNA fragmentation exists, but it requires a specific sperm sample processing and the results are obtained in delay-time. In our study we are going to also assess the correlation between sperm DNA fragmentation and sORP (static oxidation reduction potential) degree by the use of "MiOXSYS". Therefore, the availability of a simple and cheap instantaneous response time diagnostic test seems promising for the reproductive clinics. It allows us to advance in the diagnosis of male fertility potential and in the identification of those patients susceptible to antioxidant treatment in order to improve their reproductive results, increasing the chances of pregnancy both spontaneously or after assisted reproductive treatment

Being tested
Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity, Sham
Keywords
TetraSOD®, Infertility
Medical subject headings
Infertility, Male, Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activityDietary supplement

    Also called TetraSOD®

    Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start

  • ShamDietary supplement

    Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start

Study groups in NCT04864314
Study groupRoleWhat they receive
Control groupPlacebo comparatorGroup supplemented with a daily dose of placebo
Receives: Dietary Supplement: Sham
Experimental groupExperimentalGroup supplemented with a daily dose of TetraSOD®
Receives: Dietary Supplement: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sperm Progressive Motility

    Sperm progressive motility (in percentage) will be assessed according to the method described in the WHO (World Health Organization) laboratory manual for the examination and processing of human semen, 5th ed. Geneva: World Health Organization (2010)

    Measured: 90 days

  2. Sperm Concentration

    Sperm concentration will be determined according to the method described in the WHO laboratory manual for the examination and processing of human semen, 5th ed. Geneva: World Health Organization (2010)

    Measured: 90 days

Secondary outcomes (2)
  1. DNA Integrity

    DNA integrity/fragmentation was evaluated using the COMET assay. Approximately 10,000 sperm from cryopreserved samples were embedded in 1% low-melting-point agarose gel and subjected to lysis. Slides were immersed in either neutral or alkaline electrophoresis buffer for 30 min, followed by electrophoresis at 22 V for 10-15 min, maintaining current below 280 mA to prevent overheating. DNA was then stained with SYBR™ Gold (Invitrogen™, ThermoFisher scientific©, USA) and visualized by fluorescence microscopy. DNA fragments migrated further than intact chromatin, forming a characteristic comet tail. The percentage of fragmented sperm was quantified by analyzing 60-120 cells per sample.

    Measured: 90 days

  2. Adverse Effects

    Any kind of adverse event attributable to TetraSOD® will be recorded during the duration of the trial

    Measured: 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2021
  2. Study start12 May 2021
  3. Primary completion30 Jun 2024
  4. Study completion31 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04864314
Sponsor's protocol ID
2020_TSOD_01
Status last verified
Mar 2026
First submitted
24 Apr 2021
Last updated
27 Mar 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity in people with Infertility, Male, run by Fitoplancton Marino, S.L. at 2 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sperm Progressive Motility (time frame: 90 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in